Crispr Therapeutics, Sirius Therapeutics to commercialize siRNA therapies

Crispr Therapeutics (CRSP) and Sirius Therapeutics announced a strategic partnership to develop and commercialize siRNA therapies. Under the terms of the agreement, Crispr Therapeutics will make an upfront payment of $25M in cash and $70M in equity to Sirius Therapeutics. The companies will jointly develop SRSD107 under a 50-50 cost and profit-sharing structure. Crispr Therapeutics will lead commercialization in the U.S., while Sirius will be responsible for commercialization in Greater China. Additionally, Crispr Therapeutics will have the option to nominate up to two siRNA targets for research and development. For each target, Crispr Therapeutics will fund research and retain opt-in rights to lead clinical development and commercialization. Sirius will be eligible to receive milestone payments, as well as tiered royalties ranging from high single to low-double digits.